Suppr超能文献

探索甜菊糖苷与积极参与信号通路的各种蛋白质和受体的结合亲和力,以及糖尿病患者未来的候选药物。

Exploring stevioside binding affinity with various proteins and receptors actively involved in the signaling pathway and a future candidate for diabetic patients.

作者信息

Khan Salman, Ahmad Nisar, Fazal Hina, Saleh Ibrahim A, Abdel-Maksoud Mostafa A, Malik Abdul, AbdElgayed Gehad, Jalal Arshad, Rauf Kamran, Ali Liaqat, Ullah Sami, Ahmad Sajjad

机构信息

Center for Biotechnology and Microbiology, University of Swat, Swat, Pakistan.

Pakistan Council of Scientific and Industrial Research (PCSIR) Laboratories Complex, Peshawar, Pakistan.

出版信息

Front Pharmacol. 2024 Aug 7;15:1377916. doi: 10.3389/fphar.2024.1377916. eCollection 2024.

Abstract

Diabetes is a chronic metabolic disease characterized by elevated blood glucose levels and is one of the main global health concerns. Synthetic sugar substrate has many side effects such as leukemia, bladder cancer, hepatotoxicity, breast cancer, headache, and brain toxicity. The WHO and FDA has recently banned some of the synthetic sugar alternatives due to their carcinogenic effects. Therefore, the main objective of the current study was to investigate the safety and binding affinity of Stevioside with Glucose Transpoter-4 (GLUT-4), Akt, Insulin Receptor (IR) and Insulin Receptor Substrate-1 (IRS-1) to confirmed that Stevioside is one the potent natural sweetener/drug for diabetes. This study delves into the molecular interaction between Stevioside and key diabetic proteins: GLUT-4, Akt, IR and IRS-1. A precise molecular docking approach was used to simulate the binding affinity of Stevioside to these proteins. The pharmacokinetic properties of the molecule should be taken into consideration as important variables throughout the virtual screening process. The result of active site analysis of GLUT-4, Akt, IR and IRS-1 showed a zone of 2158.359 Ǻ, 579.259 Ǻ, 762.651 Ǻ, and 152.167 Ǻ and a volume of 2765.094 Ǻ³, 355.567 Ǻ³, 686.806 Ǻ³, and 116.874 Ǻ³, respectively. Docking analysis of the Stevioside compound showed the highest docking energy with scores of -9.9 with GLUT-4, -6.7 with Akt, -8.0 with IR and -8.8 with IRS-1. Studies indicated that it remains undigested by stomach acids and enzymes and is not absorbed in the upper small intestine. Further, tests revealed no hepatotoxicity, AMES toxicity, or skin sensitivity, making it a promising candidate for safe consumption as drug metabolism. Instead of other sugar alternatives, Stevioside will help diabetic patients with a lower chance of infections, lowered blood pressure/blood sugar, and increased glucose uptake in diabetic muscles. Stevioside is a natural sweetener, and the current study recommends its usage in various dietary products for diabetic patients.

摘要

糖尿病是一种以血糖水平升高为特征的慢性代谢性疾病,是全球主要的健康问题之一。合成糖底物有许多副作用,如白血病、膀胱癌、肝毒性、乳腺癌、头痛和脑毒性。由于其致癌作用,世界卫生组织(WHO)和美国食品药品监督管理局(FDA)最近已禁止了一些合成糖替代品。因此,本研究的主要目的是研究甜菊糖苷与葡萄糖转运蛋白4(GLUT - 4)、蛋白激酶B(Akt)、胰岛素受体(IR)和胰岛素受体底物 - 1(IRS - 1)的安全性和结合亲和力,以证实甜菊糖苷是一种有效的糖尿病天然甜味剂/药物。本研究深入探讨了甜菊糖苷与关键糖尿病蛋白GLUT - 4、Akt、IR和IRS - 1之间的分子相互作用。采用精确的分子对接方法来模拟甜菊糖苷与这些蛋白质的结合亲和力。在整个虚拟筛选过程中,应将该分子的药代动力学性质作为重要变量加以考虑。对GLUT - 4、Akt、IR和IRS - 1的活性位点分析结果显示,其区域分别为2158.359 Å、579.259 Å、762.651 Å和152.167 Å,体积分别为2765.094 ų、355.567 ų、686.806 ų和116.874 ų。甜菊糖苷化合物的对接分析显示,其与GLUT - 4的对接能量最高,得分为 - 9.9,与Akt为 - 6.7,与IR为 - 8.0,与IRS - 1为 - 8.8。研究表明,它不会被胃酸和酶消化,也不会在小肠上段被吸收。此外,测试显示没有肝毒性、AMES毒性或皮肤敏感性,这使其成为药物代谢安全消费的有前景的候选物。与其他糖替代品不同,甜菊糖苷将有助于糖尿病患者降低感染几率、降低血压/血糖,并增加糖尿病肌肉中的葡萄糖摄取。甜菊糖苷是一种天然甜味剂,目前的研究建议将其用于糖尿病患者的各种膳食产品中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3521/11335537/73dc0588d064/fphar-15-1377916-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验